Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fallowfield

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Scientific Reports|June 17, 2018
Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational studyNatasha McDonald, Peter J Eddowes, James Hodson, et al.
Molecular Metabolism|June 2, 2026
TGFβ activity stabilizes ACC1 to increase de novo lipogenesis in metabolic liver diseaseBrent Mayfield, Yoko Yagashita, Jinku Kang, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2012
Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosisPrakash Ramachandran, Antonella Pellicoro, Madeleine A Vernon, et al.
Nature Medicine|October 31, 2023
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver diseaseTimothy J Kendall, Maria Jimenez-Ramos, Frances Turner, et al.
Plos One|December 2, 2020
Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancerDamian J Mole, Jonathan A Fallowfield, Ahmed E Sherif, et al.
Hepatology Communications|November 25, 2024
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767Prakash Ramachandran, Madara Brice, Elena F Sutherland, et al.
Nature Medicine|October 9, 2019
Safety profile of autologous macrophage therapy for liver cirrhosisFrancesca Moroni, Benjamin J Dwyer, Catriona Graham, et al.
Nature Medicine|January 10, 2025
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trialPaul N Brennan, Mark MacMillan, Thomas Manship, et al.
Hepatology Communications|September 18, 2021
Genome-Wide Association Study of NAFLD Using Electronic Health RecordsCameron J Fairfield, Thomas M Drake, Riinu Pius, et al.
Hepatology (Baltimore, Md.)|October 15, 2021
Genome-wide analysis identifies gallstone-susceptibility loci including genes regulating gastrointestinal motilityCameron J Fairfield, Thomas M Drake, Riinu Pius, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Scientific Reports|June 17, 2018
Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational studyNatasha McDonald, Peter J Eddowes, James Hodson, et al.
Molecular Metabolism|June 2, 2026
TGFβ activity stabilizes ACC1 to increase de novo lipogenesis in metabolic liver diseaseBrent Mayfield, Yoko Yagashita, Jinku Kang, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2012
Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosisPrakash Ramachandran, Antonella Pellicoro, Madeleine A Vernon, et al.
Nature Medicine|October 31, 2023
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver diseaseTimothy J Kendall, Maria Jimenez-Ramos, Frances Turner, et al.
Plos One|December 2, 2020
Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancerDamian J Mole, Jonathan A Fallowfield, Ahmed E Sherif, et al.
Hepatology Communications|November 25, 2024
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767Prakash Ramachandran, Madara Brice, Elena F Sutherland, et al.
Nature Medicine|October 9, 2019
Safety profile of autologous macrophage therapy for liver cirrhosisFrancesca Moroni, Benjamin J Dwyer, Catriona Graham, et al.
Nature Medicine|January 10, 2025
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trialPaul N Brennan, Mark MacMillan, Thomas Manship, et al.
Hepatology Communications|September 18, 2021
Genome-Wide Association Study of NAFLD Using Electronic Health RecordsCameron J Fairfield, Thomas M Drake, Riinu Pius, et al.
Hepatology (Baltimore, Md.)|October 15, 2021
Genome-wide analysis identifies gallstone-susceptibility loci including genes regulating gastrointestinal motilityCameron J Fairfield, Thomas M Drake, Riinu Pius, et al.
Pageof 7